PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Abeona Therapeutics Inc. (ABEO)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS00289Y1073
CUSIP00289Y107
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$214.54M
EPS-$1.37
Revenue (TTM)$3.57M
Gross Profit (TTM)-$28.00M
EBITDA (TTM)-$44.45M
Year Range$2.24 - $9.01
Target Price$21.50
Short %7.30%
Short Ratio4.12

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds to compare with ABEO

Abeona Therapeutics Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Abeona Therapeutics Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%1,000.00%2,000.00%3,000.00%4,000.00%OctoberNovemberDecember2024FebruaryMarch
-100.00%
3,859.06%
ABEO (Abeona Therapeutics Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Abeona Therapeutics Inc. had a return of 72.26% year-to-date (YTD) and 261.09% in the last 12 months. Over the past 10 years, Abeona Therapeutics Inc. had an annualized return of -35.01%, while the S&P 500 had an annualized return of 10.61%, indicating that Abeona Therapeutics Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date72.26%7.28%
1 month23.11%2.23%
6 months114.14%14.98%
1 year261.09%30.65%
5 years (annualized)-46.72%12.59%
10 years (annualized)-35.01%10.61%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-18.76%69.53%
202329.53%-4.97%-9.26%25.65%4.37%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

This table presents risk-adjusted performance metrics for Abeona Therapeutics Inc. (ABEO) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
ABEO
Abeona Therapeutics Inc.
3.27
^GSPC
S&P 500
2.64

Sharpe Ratio

The current Abeona Therapeutics Inc. Sharpe ratio is 3.27. A Sharpe ratio of 3.0 or higher is considered excellent.


Rolling 12-month Sharpe Ratio0.001.002.003.00OctoberNovemberDecember2024FebruaryMarch
3.27
2.64
ABEO (Abeona Therapeutics Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Abeona Therapeutics Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%OctoberNovemberDecember2024FebruaryMarch
-100.00%
-1.12%
ABEO (Abeona Therapeutics Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Abeona Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Abeona Therapeutics Inc. was 100.00%, occurring on Feb 24, 2023. The portfolio has not yet recovered.

The current Abeona Therapeutics Inc. drawdown is 100.00%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-100%Jan 28, 19927620Feb 24, 2023
-88.54%Feb 18, 1988712Dec 12, 1990272Jan 13, 1992984
-39.84%Nov 3, 198723Dec 4, 198723Jan 8, 198846
-36.97%May 22, 198452Aug 7, 198413Aug 27, 198465
-28.38%Aug 31, 198412Sep 18, 19844Sep 24, 198416

Volatility

Volatility Chart

The current Abeona Therapeutics Inc. volatility is 22.81%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%35.00%OctoberNovemberDecember2024FebruaryMarch
22.81%
3.36%
ABEO (Abeona Therapeutics Inc.)
Benchmark (^GSPC)

Financials

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM2023202220212020
Revenue

Total Revenue

3.50M3.57M1.41M3.00M10.00M

Cost Of Revenue

2.49M1.71M450.00K4.46M30.14M

Gross Profit

1.01M1.86M964.00K-1.46M-20.14M
Operating Expenses

Selling, General & Admin Expenses

13.17M18.86M17.26M22.80M23.78M

R&D Expenses

23.71M29.98M28.97M34.33M30.14M

Total Operating Expenses

36.89M50.55M46.22M60.37M58.50M
Income

Income Before Tax

-37.60M-44.72M-39.70M-84.94M-84.23M

Operating Income

-33.93M-46.98M-45.26M-89.84M-81.42M

EBIT

-33.11M0.00-45.26M-89.84M-81.42M

Earnings From Continuing Operations

-36.90M-44.72M-39.70M-84.94M-84.23M

Net Income

-34.77M-44.72M-31.81M-88.61M-88.35M

Income Tax Expense

-1.26M0.00-7.89M3.67M4.12M

Interest Expense

99.00K487.00K736.00K3.67M4.12M

Other Non-Operating Income (Expenses)

-2.92M1.04M5.56M4.90M-2.81M

Extraordinary Items

0.000.000.000.000.00

Discontinued Operations

0.000.000.000.000.00

Effect Of Accounting Charges

0.000.000.000.000.00

Non Recurring

1.58M0.000.000.000.00

Minority Interest

0.000.000.000.000.00

Other Items

0.000.000.000.000.00
Values in USD except per share items